MannKind Corporation has had the most explosive week in its recent history — up 19% in five sessions to $3.53 — and the bears are on the wrong side of it.
Short interest has been creeping higher this week even as the stock surged. SI climbed to 9.77% of the free float, up from around 9.25% at the start of the month, after falling from a peak near 10.2% in late April. The move higher in shorts during a strong price week suggests some sellers were adding into strength rather than covering — a setup that could amplify the next leg if they capitulate. The ORTEX short score has also ticked up steadily, from 51.7 two weeks ago to 55.9 today, its highest reading in the observed window.
The borrow market offers the shorts little concern for now. Cost to borrow remains cheap at 0.45% annualised — up only about 9% on the week and essentially flat over the past month. Availability is ample at 450%, well above the 52-week low of 388%, meaning there is no structural squeeze pressure in the lending pool. Options traders are actually leaning bullish: the put/call ratio is running at 0.28, below its 20-day average of 0.32 and about one standard deviation below the norm. The PCR has been drifting lower since late April when it sat near 0.38 — that's a sustained rotation into calls through the rally. The 52-week low on the PCR is 0.054, so there's room for this positioning to extend, but the direction of travel is clear.
The Street is broadly constructive, though with some nuance. Following the Q1 earnings beat on May 6 — when the stock jumped 24% in a day — Wells Fargo raised its target to $10 and Mizuho trimmed slightly to $7, both keeping positive ratings. RBC moved its target from $3.50 to $4.75 but remained neutral. The consensus mean target is $7.22 against today's $3.53 price, implying substantial upside according to analysts — though the stock needs to nearly double from here to get there. The bull case rests on Tyvaso DPI royalty growth and potential expansion into idiopathic pulmonary fibrosis; the bear case flags competition from Boehringer Ingelheim's Jascayd and patent risk as real constraints on how far the growth story can run. The trailing PE has expanded to 27.6x — up from about 22x a month ago — as the stock recovered.
Insider activity adds a subtle subplot. CEO Michael Castagna bought 100,000 shares in March at $2.59, a meaningful signal at the time. He then sold 34,957 shares on May 11 at $3.52 — capturing a 36% gain on that purchase in roughly two months. The director and general counsel also trimmed on May 11 and 12. None of the values are large in dollar terms (all sub-$125K), but the cluster of sales right at the post-earnings high is worth noting. The net 90-day insider position is modestly positive at roughly 193,000 shares, largely reflecting that March CEO buy.
Institutional flows reveal a few notable moves. State Street added over four million shares as recently as April 30. Millennium Management built a near-6.4 million share position in Q1. Rubric Capital, by contrast, trimmed by over 3.8 million shares — the largest outflow in the top-15 holder list.
The next earnings date is August 7. With shorts still near 10% of float, the PCR drifting lower, and a 19% price surge this week following a 24% single-day pop on May 6, the question is whether the sellers rebuilding positions this week have conviction — or whether that same short base becomes the fuel for further covering.
See the live data behind this article on ORTEX.
Open MNKD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
